The critical role of flow cytometry in CAR+ T-Cell trials

In this interview, Ryan Muise talks to AZoNetwork about the added value of using flow cytometry in CAR T-Cell clinical trials.

Related Keywords

Australia ,China ,Germany ,Taiwan ,France ,French ,German ,Louis Castel ,Cerba Researchdec ,Cytek Aurora ,Rowan Claeys ,University Of Ghent ,Ans De Beuckelaer Rowan Clayescerba Research ,Flow Cytometry Department ,Cerba Research ,University Of Louvain ,Sponsored Content ,Ans De Beuckelaer ,Rowan Clayescerba ,Flow Cytometry ,Jim Rowan ,Minual Residual Disease ,Minimal Residual Disease ,Next Generation Flow Cytometry ,Cart Cell ,Fell ,Ytometry ,T Cell ,Antibodies ,Ntibody ,Ntigen ,Essay ,B Cell ,Biotechnology ,Flood ,One ,Bone Marrow ,Dd3 ,D4 ,Clinical Trial ,Iagnostic ,Iagnostics ,Doctor ,Drugs ,Efficacy ,Exhaustion ,Flu ,Genes ,Hematology ,High Throughput ,Hospital ,Maging ,Imaging Techniques ,Mmunophenotyping ,Immunotherapy ,Laboratory ,Leukemia ,Leukocyte ,Alignant ,Multiple Myeloma ,Myeloma ,Mh ,Pharmacokinetics ,Henotype ,Eceptor ,Research ,Running ,Humor ,